Presentation is loading. Please wait.

Presentation is loading. Please wait.

Serum neutralizing antibody response of BALB/c mice to DNA prime followed by VRP boost. Serum neutralizing antibody response of BALB/c mice to DNA prime.

Published byRoland Burgstaller Modified over 5 years ago

Similar presentations

Presentation on theme: "Serum neutralizing antibody response of BALB/c mice to DNA prime followed by VRP boost. Serum neutralizing antibody response of BALB/c mice to DNA prime."— Presentation transcript:

1 Serum neutralizing antibody response of BALB/c mice to DNA prime followed by VRP boost.
Serum neutralizing antibody response of BALB/c mice to DNA prime followed by VRP boost. Microneutralization titers against HK/Syd (2,000 TCID50 ml−1) at day 21 of the quaternary response to the vaccine are reported. Data are reported for the following numbers of mice in the various groups: for vector DNA plus PBS, n = 8; for vector DNA plus GFP-VRP, n = 15; for vector DNA plus HA-VRP, n = 15; for HA-DNA plus PBS, n = 10; for HA-DNA plus GFP-VRP, n = 17; and for HA-DNA plus HA-VRP, n = 18. An asterisk indicates a significant difference in titer compared to those for groups inoculated with vector DNA (P < 0.01 by ANOVA). Victor C. Huber et al. Clin. Vaccine Immunol. 2006; doi: /CVI

Download ppt "Serum neutralizing antibody response of BALB/c mice to DNA prime followed by VRP boost. Serum neutralizing antibody response of BALB/c mice to DNA prime."

Similar presentations

Fig. 2.The intestinal secretory IgA (sIgA) antibody response was measured in chickens against the outer membrane protein for 7 weeks PPI. Antibody levels.

Fig. 2.The intestinal secretory IgA (sIgA) antibody response was measured in chickens against the outer membrane protein for 7 weeks PPI. Antibody levels.
Serum IgG (A–D) and IgA (E–H) titer from BALB/c mice (n = 5/group) at day 0 or following COBRA P1 virus i.n., i.p., or i.m. prime at day 21 or following.

Serum IgG (A–D) and IgA (E–H) titer from BALB/c mice (n = 5/group) at day 0 or following COBRA P1 virus i.n., i.p., or i.m. prime at day 21 or following.
Volume 25, Issue 6, Pages (June 2017)

Volume 25, Issue 6, Pages (June 2017)
In vivo prophylactic and therapeutic efficacy of C12G6 in mice

In vivo prophylactic and therapeutic efficacy of C12G6 in mice
FMDV-specific IgG, IgG1, and IgG2 in sera of guinea pigs (n = 6/group) immunized on days 1 and 21 by intramuscular injection of FMDV antigens (type O)

FMDV-specific IgG, IgG1, and IgG2 in sera of guinea pigs (n = 6/group) immunized on days 1 and 21 by intramuscular injection of FMDV antigens (type O)
HA-specific Abs in serum 14 d after a single vaccination with the various targeted DNA vaccines. HA-specific Abs in serum 14 d after a single vaccination.

HA-specific Abs in serum 14 d after a single vaccination with the various targeted DNA vaccines. HA-specific Abs in serum 14 d after a single vaccination.
A single DNA vaccination of C57BL/6 mice induced Ab responses of IgG1 and/or IgG2c subclass. A single DNA vaccination of C57BL/6 mice induced Ab responses.

A single DNA vaccination of C57BL/6 mice induced Ab responses of IgG1 and/or IgG2c subclass. A single DNA vaccination of C57BL/6 mice induced Ab responses.
Serum IgG subclass representation from BALB/c mice (n = 5/group) following COBRA P1 virus i.n., i.p., or i.m. prime followed by i.p. or i.m. boost. Serum.

Serum IgG subclass representation from BALB/c mice (n = 5/group) following COBRA P1 virus i.n., i.p., or i.m. prime followed by i.p. or i.m. boost. Serum.
Virus-specific serum antibody response of BALB/c mice to DNA prime followed by VRP boost. Virus-specific serum antibody response of BALB/c mice to DNA.

Virus-specific serum antibody response of BALB/c mice to DNA prime followed by VRP boost. Virus-specific serum antibody response of BALB/c mice to DNA.
Volume 26, Issue 2, Pages (February 2018)

Volume 26, Issue 2, Pages (February 2018)
Protection from influenza virus challenge.

Protection from influenza virus challenge.
FMD VP1-specific IgG, IgG1, and IgG2 in sera of guinea pigs (n = 6/group) immunized on days 1 and 21 by intramuscular injection of FMDV antigens (type.

FMD VP1-specific IgG, IgG1, and IgG2 in sera of guinea pigs (n = 6/group) immunized on days 1 and 21 by intramuscular injection of FMDV antigens (type.
Detection of CSFV-specific antibodies in immunized/challenged pigs using blocking ELISA. Groups of pigs (n = 5) were inoculated with different doses of.

Detection of CSFV-specific antibodies in immunized/challenged pigs using blocking ELISA. Groups of pigs (n = 5) were inoculated with different doses of.
Virus-specific serum antibody response of BALB/c mice to DNA prime followed by VRP boost. Virus-specific serum antibody response of BALB/c mice to DNA.

Virus-specific serum antibody response of BALB/c mice to DNA prime followed by VRP boost. Virus-specific serum antibody response of BALB/c mice to DNA.
Immune response to vaccination with AVA in healthy human subjects (human immunogenicity study). Immune response to vaccination with AVA in healthy human.

Immune response to vaccination with AVA in healthy human subjects (human immunogenicity study). Immune response to vaccination with AVA in healthy human.
Survival of BALB/c mice after HK/Syd challenge.

Survival of BALB/c mice after HK/Syd challenge.
CCL19 levels are elevated in Lyme disease cases with PTLDS

CCL19 levels are elevated in Lyme disease cases with PTLDS
CD4 T cells are responsible for the intensified joint pathology at 6 d postinfection. CD4 T cells are responsible for the intensified joint pathology at.

CD4 T cells are responsible for the intensified joint pathology at 6 d postinfection. CD4 T cells are responsible for the intensified joint pathology at.
Comparison of relative activity of Adjuplex and other commonly used adjuvants. Comparison of relative activity of Adjuplex and other commonly used adjuvants.

Comparison of relative activity of Adjuplex and other commonly used adjuvants. Comparison of relative activity of Adjuplex and other commonly used adjuvants.
Antibody endpoint titers induced by PfCelTOS vaccines containing various adjuvant formulations with emulsion doses of 0.5% to 2% (vol/vol) oil, as measured.

Antibody endpoint titers induced by PfCelTOS vaccines containing various adjuvant formulations with emulsion doses of 0.5% to 2% (vol/vol) oil, as measured.

Similar presentations

Ads by Google